Scientific Programme Wednesday, 10 October 2018

1 Scientific ProgrammeWednesday, 10 October 2018 Hot Topic, Hall B08:00 - 08:45 Hot Topic 1: Hot topics in MS neuropathologyChairsM. Inglese (New York, US)R. Reynolds (London, UK)08:00 - 08:151 Myelocortical multiple sclerosis: cortical neuronal loss in the absence ofcerebral white matter demyelination B. Trapp (Cleveland, US)08:15 - 08:302 Meningeal inflammation as a driver of cortical pathology R. Magliozzi (Verona, IT)08:30 - 08:453 Pathology of radiologically isolated syndrome C. Lucchinetti (Rochester, US)Educational Session, Hall D08:00 - 09:30 Educational Session 1: Pregnancy management in MSLevel: BasicChairsK. Hellwig (Bochum, DE)A. Langer-Gould (Pasadena, US)08:00 - 08:304 Symptomatic treatment of MS and pregnancy / lactation management M. Magyari (Copenhagen, DK)08:30 - 09:005 The natural history of MS during pregnancy and the postpartum period incontemporary MS cohort A.

2 Langer-Gould (Pasadena, US)09:00 - 09:306MS medication in people with MS planning a pregnancy: an update K. Hellwig (Bochum, DE)Educational Session, Hall E08:00 - 09:30 Educational Session 2: Practical treatmentrecommendations based on new guidelines in MSLevel: BasicChairsX. Montalban (Toronto, CA)D. Pelletier (Los Angeles, US)Page 1 / 117 Scientific Programme08:00 - 08:307 ECTRIMS/EAN MS treatment guidelines X. Montalban (Toronto, CA)08:30 - 09:008 AAN treatment guidelines D. Pelletier (Los Angeles, US)09:00 - 09:309 What else is needed in real life and is not covered by the guidelines? T. Kalincik (Melbourne, AU)Educational Session, Hall F08:00 - 09:30 Educational Session 3: Neurofilament light chains in MS:where do we stand, the long road to clinical applicationLevel: IntermediateChairsC.

3 Teunissen (Amsterdam, NL)F. Piehl (Stockholm, SE)08:00 - 08:3010 The long road to clinical application: where do we stand withneurofilament light chain in MS? D. Leppert (Basel, CH)08:30 - 09:0011 The long road to clinical implementation C. Teunissen (Amsterdam, NL)09:00 - 09:3012 Clinical application today and tomorrow F. Piehl (Stockholm, SE)Educational Session, Hall G08:00 - 09:30 Educational Session 5: Impact and management ofcomorbidities in MSLevel: Marrie (Winnipeg, CA)H. Tremlett (Vancouver, CA)08:00 - 08:3016 The impact of comorbidity on multiple sclerosis Marrie (Winnipeg, CA)08:30 - 09:0017 Bidirectional relationships between comorbidity and disease-modifyingtherapy H. Tremlett (Vancouver, CA)09:00 - 09:3018 Management of psychiatric comorbidity in multiple sclerosis A.

4 Feinstein (Toronto, CA)Page 2 / 117 Scientific ProgrammeEducational Session, Hall H08:00 - 09:30 Educational Session 4: Immunology of MSLevel: AdvancedChairsE. Meinl (Martinsried, DE) Yong (Calgary, CA)08:00 - 08:3013B cells and T cells in MS E. Meinl (Martinsried, DE)08:30 - 09:0014 Myeloid cells in MS Yong (Calgary, CA)09:00 - 09:3015 Systems Immunology to model, predict and monitor multiple sclerosis C. Farina (Milan, IT)Hot Topic, Hall B08:55 - 09:40 Hot Topic 2: Digital MS: improving data acquisition andanalysisChairsJ. Haas (Berlin, DE)M. Magyari (Copenhagen, DK)08:55 - 09:1019 Towards standardisation of clinical documentation in MS M. D'Souza (Basel, CH)09:10 - 09:2520 Automated MR image analysis Arnold (Montreal, CA)09:25 - 09:4021 Using mobile devices for patient reported outcomes T.

5 Ziemssen (Dresden, DE)Young Scientific Investigators' Session, Hall C09:00 - 10:15 Young Scientific Investigators' Session 1: Freedman (Ottawa, CA) Harbo (Oslo, NO)09:00 - 09:1522 Demyelination, inflammation and axonal loss explain different patternsof fractional anisotropy abnormalities in MS cortical normal apperinggray matter and lesions P. Preziosa (Amsterdam, NL)09:15 - 09:3023 Multicentre MAGNIMS study group trial investigating the correlationbetween cortical and periventricular pathology in MS L. Pirpamer (Graz, AT)Page 3 / 117 Scientific Programme09:30 - 09:4524 MRI brain T1 gray matter/white matter contrast in multiple sclerosisversus migraine using magnetization prepared rapid gradient echo(MPRAGE) sequences T. Mitrovic (Basel, CH)09:45 - 10:0025T1-weighted signal intensity change in the dentate nucleus of MSpatients after repeated application of linear and macrocyclic gadolinium-based contrast agents S.

6 Grahl (Munich, DE)10:00 - 10:1526 Brain age estimation in a longitudinal cohort of patients with multiplesclerosis H gest l (Oslo, NO)Hot Topic, Hall B09:45 - 10:30 Hot Topic 3: Biosimilars and follow-upsChairsJ. Hillert (Stockholm, SE)A. Wilkins (Bristol, UK)09:45 - 10:0027 Regulator's perspective R. Anour (Vienna, AT)10:00 - 10:1528 Generic, biosimilar and complex non-biologic follow-on drugs: theclinician's perspective J. Cohen (Cleveland, US)10:15 - 10:3029 The European biosimilar experience: lessons learned from a maturingmarket U. Banning (Frankfurt, DE)Hot Topic, Hall D09:45 - 10:30 Hot Topic 4: New approaches for microscopic andmacroscopic imagingChairsJ. Antel (Montreal, CA)B. Stankoff (Paris, FR)09:45 - 10:0030In vivo brain imaging in experimental models T. Misgeld (Munich, DE)10:00 - 10:1531 MRI based molecular imaging C.

7 Stagg (Oxford, UK)10:15 - 10:3032 PET based molecular imaging B. Bodini (Paris, FR)Page 4 / 117 Scientific ProgrammeHot Topic, Hall E09:45 - 10:30 Hot Topic 5: Mechanisms of CNS autoimmunityChairsR. Liblau (Toulouse, FR)M. Friese (Hamburg, FR)09:45 - 10:0033 Innate immunity M. Prinz (Freiburg, DE)10:00 - 10:1534B and T cells in multiple sclerosis T. Korn (Munich, DE)10:15 - 10:3035 Blood brain barrier A. Prat (Montreal, CA)Educational Session, Hall F09:45 - 10:30 Case-based Educational Session 6: How to manage non-response to highly active (second line) drugs? Coles (Cambridge, UK)J. Sastre-Garriga (Barcelona, ES)09:45 - 10:0736 Case 1 Coles (Cambridge, UK)10:07 - 10:2937 Case 2 J. Sastre-Garriga (Barcelona, ES)Educational Session, Hall G09:45 - 10:30 Case-based Educational Session 7: Progressive MS: whoshould be treated and how to monitor treatmentresponse?

8 Cree (San Francisco, US) S rensen (Copenhagen, DK)09:45 - 10:0738 Case 1 Cree (San Francisco, US)10:07 - 10:2939 Case 2 S rensen (Copenhagen, DK)Page 5 / 117 Scientific ProgrammeEducational Session, Hall H09:45 - 10:30 Case-based Educational Session 8: Should all MS patientsbe treated?ChairsA. Chan (Bern, CH)M. Stangel (Hannover, DE)09:45 - 10:0740 Pro M. Stangel (Hannover, DE)10:07 - 10:2941 Con A. Chan (Bern, CH)Plenary Session, Hall A11:00 - 12:15 Plenary Session 1: Welcome and ECTRIMS LectureChairsR. Hohlfeld (Munich, DE)B. Hemmer (Munich, DE)D. Miller (London, UK)11:00 - 11:3042 Welcome to ECTRIMS 2018 D. Miller (London, UK) R. Hohlfeld (Munich, DE)11:30 - 12:1543 Multiple sclerosis in the digital age: 'seeing through a glass darkly' A. Compston (Cambridge, UK)Satellite Symposium, Hall A12:30 - 13:30 Satellite Symposium 1: Data Analysis Technology Application developments on the frontiers of MSSupported by Biogen* the approved dosing schedule for natalizumab is 300 mg once every 4 Hartung (D sseldorf, DE)12:30 - 12:3544 Introduction Hartung (D sseldorf, DE)12:35 - 12:4545 The clinical data on extended interval dosing (EID) with natalizumab* J.

9 Foley (Salt Lake City, US)12:45 - 13:0046 Biological hypotheses and experimental approaches suggested byavailable natalizumab data Goelz (Portland, US)Page 6 / 117 Scientific Programme13:00 - 13:1047 Serum neurofilament light (sNfL) from a research point of view C. Teunissen (Amsterdam, NL)13:10 - 13:2548 The clinical relevance of serum neurofilament light (sNfL) Fox (Cleveland, US)13:25 - 13:3049 Closing remarks Hartung (D sseldorf, DE)Satellite Symposium, Hall D12:30 - 13:30 Satellite Symposium 2: THC: CBD in multiple sclerosisspasticity symptoms: newest evidence confirming efficacyand safetySupported by Almirall Ziemssen (Dresden, DE)12:30 - 12:4050 Welcome12:40 - 13:0051 THC: CBD post-approval pragmatic studies evidence F. Patti (Catania, IT)13:00 - 13:2052 THC: CBD post-approval clinical trials evidence J.

10 Markov (Prague, CZ)13:20 - 13:3053 ClosingScientific Session, Hall B13:30 - 15:00 Scientific Session 1: How real world data can informtreatment decisionsChairsS. Vukusic (Lyon, FR)O. Stuve (Dallas, US)13:30 - 13:5054 Efficacy in the real world T. Kalincik (Melbourne, AU)13:50 - 14:1055 Traps and pitfalls (methodological issues) Sormani (Genoa, IT) Platform presentations of related original papers14:10 - 14:2256 Multiple sclerosis in Germany 2018 - update on baseline data from theGerman MS Registry P. Flachenecker (Bad Wildbad, DE)Page 7 / 117 Scientific Programme14:22 - 14:3457 Determinants of disability accumulation in secondary-progressivemultiple sclerosis N. Lizak (Melbourne, AU)14:34 - 14:4658 Familial multiple sclerosis: comparing demographic and clinicalcharacteristics with sporadic form S.